Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionubiquitin-protein transferase regulator activity

BTRC SPRY2

6.23e-053572GO:0055106
MousePhenoabnormal centrosome morphology

CDC25A BTRC

1.94e-052052MP:0030943
MousePhenoabnormal microtubule organizing center morphology

CDC25A BTRC

2.36e-052252MP:0030942
MousePhenoabnormal microtubule cytoskeleton morphology

CDC25A BTRC

1.05e-044652MP:0020850
MousePhenoabnormal cell cytoskeleton morphology

CDC25A BTRC

2.81e-047552MP:0020378
MousePhenoabnormal chromosome number

CDC25A BTRC

3.70e-048652MP:0004023
MousePhenoabnormal chromosome morphology

CDC25A BTRC

7.92e-0412652MP:0003702
MousePhenoabnormal mitosis

CDC25A BTRC

8.17e-0412852MP:0004046
MousePhenoabnormal cell nucleus morphology

CDC25A BTRC

1.68e-0318452MP:0003111
MousePhenoabnormal trabecular bone morphology

CDC25A SPRY2

4.09e-0328952MP:0000130
PathwayWP_ANDROGEN_RECEPTOR_NETWORK_IN_PROSTATE_CANCER

CDC25A SPRY2

5.94e-0411052M48043
PathwayREACTOME_MITOTIC_G2_G2_M_PHASES

CDC25A BTRC

1.95e-0320052M864
PathwayREACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

CDC25A BTRC ADAMTS19

9.72e-03147553M19806
PathwayREACTOME_CELL_CYCLE_MITOTIC

CDC25A BTRC

1.46e-0256152M5336
PathwayREACTOME_CELL_CYCLE

CDC25A BTRC

2.19e-0269452M543
Pubmed

FBXW8 regulates G1 and S phases of cell cycle progression by restricting β-TrCP1 function.

CDC25A BTRC

1.04e-0737233742524
Pubmed

Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.

CDC25A BTRC

1.04e-0737220348946
Pubmed

Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles.

CDC25A BTRC

2.08e-0747217676996
Pubmed

Regulation of lung cancer cell growth and invasiveness by beta-TRCP.

CDC25A BTRC

2.08e-0747215536641
Pubmed

Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation.

CDC25A BTRC

2.08e-0747214752276
Pubmed

SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase.

CDC25A BTRC

3.47e-0757214681206
Pubmed

The p97-Ufd1-Npl4 ATPase complex ensures robustness of the G2/M checkpoint by facilitating CDC25A degradation.

CDC25A BTRC

3.47e-0757224429874
Pubmed

Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

CDC25A BTRC

3.47e-0757215798217
Pubmed

The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival.

CDC25A BTRC

5.21e-0767219966869
Pubmed

Identification of substrates for F-box proteins.

CDC25A BTRC

7.29e-0777216338364
Pubmed

Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways.

CDC25A BTRC

1.25e-0697219477924
Pubmed

CENP-W inhibits CDC25A degradation by destabilizing the SCFβ-TrCP-1 complex at G2/M.

CDC25A BTRC

1.25e-0697229863914
Pubmed

Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage.

CDC25A BTRC

1.56e-06107214603323
Pubmed

mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

CDC25A BTRC

8.77e-06237222017875
Pubmed

CRL4AMBRA1 is a master regulator of D-type cyclins.

CDC25A BTRC

1.51e-05307233854235
Pubmed

DNA Damage Regulates Translation through β-TRCP Targeting of CReP.

CDC25A BTRC

2.06e-05357226091241
Pubmed

The E3 ubiquitin ligase APC/CCdh1 degrades MCPH1 after MCPH1-βTrCP2-Cdc25A-mediated mitotic entry to ensure neurogenesis.

CDC25A BTRC

7.18e-05657229150431
CoexpressionWEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2

CDC25A SPRY2

3.83e-053672M347
CoexpressionBASSO_HAIRY_CELL_LEUKEMIA_UP

RNF11 SPRY2

1.87e-047972M13859
CoexpressionBONCI_TARGETS_OF_MIR15A_AND_MIR16_1

CDC25A BTRC

2.53e-049272M11682
CoexpressionGSE13887_HEALTHY_VS_LUPUS_RESTING_CD4_TCELL_DN

BTRC RNF11

4.74e-0412672M475
CoexpressionCASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP

RNF11 SPRY2

9.00e-0417472M2038
CoexpressionLASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN

CDC25A BTRC RNF11

9.28e-0480773M14594
CoexpressionIL15_UP.V1_UP

CDC25A SPRY2

1.06e-0318972M2819
CoexpressionIL2_UP.V1_UP

CDC25A SPRY2

1.07e-0319072M2822
CoexpressionGSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_3H_UP

SPRY2 CARD19

1.08e-0319172M8251
CoexpressionP53_DN.V1_UP

RNF11 SPRY2

1.12e-0319472M2698
CoexpressionGSE34156_TLR1_TLR2_LIGAND_VS_NOD2_AND_TLR1_TLR2_LIGAND_24H_TREATED_MONOCYTE_UP

ADAMTS19 CARD19

1.15e-0319772M8676
CoexpressionGSE3982_BCELL_VS_TH1_DN

CDC25A SPRY2

1.16e-0319872M5553
CoexpressionGSE20151_CTRL_VS_FUSOBACT_NUCLEATUM_NEUTROPHIL_UP

CDC25A SPRY2

1.16e-0319872M4309
CoexpressionGSE14308_TH2_VS_NATURAL_TREG_UP

SPRY2 CARD19

1.17e-0319972M3368
CoexpressionGSE17721_POLYIC_VS_CPG_12H_BMDC_DN

CDC25A RNF11

1.19e-0320072M3949
CoexpressionGSE11961_FOLLICULAR_BCELL_VS_MARGINAL_ZONE_BCELL_UP

BTRC RNF11

1.19e-0320072M9381
CoexpressionGSE14908_ATOPIC_VS_NONATOPIC_PATIENT_RESTING_CD4_TCELL_UP

RNF11 CARD19

1.19e-0320072M7092
CoexpressionGSE17721_POLYIC_VS_PAM3CSK4_2H_BMDC_UP

CDC25A CARD19

1.19e-0320072M3830
CoexpressionGSE17721_PAM3CSK4_VS_CPG_2H_BMDC_DN

CDC25A CARD19

1.19e-0320072M3858
CoexpressionGSE43955_TGFB_IL6_VS_TGFB_IL6_IL23_TH17_ACT_CD4_TCELL_52H_UP

CDC25A BTRC

1.19e-0320072M9667
CoexpressionGSE21379_TFH_VS_NON_TFH_CD4_TCELL_UP

BTRC RNF11

1.19e-0320072M7500
CoexpressionGSE30971_WBP7_HET_VS_KO_MACROPHAGE_2H_LPS_STIM_UP

SPRY2 CARD19

1.19e-0320072M8722
CoexpressionGSE21546_ELK1_KO_VS_SAP1A_KO_AND_ELK1_KO_ANTI_CD3_STIM_DP_THYMOCYTES_DN

CDC25A SPRY2

1.19e-0320072M7531
CoexpressionGSE34392_ST2_KO_VS_WT_DAY8_LCMV_EFFECTOR_CD8_TCELL_DN

RNF11 CARD19

1.19e-0320072M8654
CoexpressionGSE339_EX_VIVO_VS_IN_CULTURE_CD4POS_DC_DN

RNF11 CARD19

1.19e-0320072M5130
CoexpressionLINSLEY_MIR16_TARGETS

CDC25A BTRC

1.26e-0320672M2284
ToppCellControl-Classical_Monocyte-cMono_3|Classical_Monocyte / Disease condition and Cell class

SPRY2 CARD19

2.17e-0414672fcd8548b42275758d7d77ad2651afe7ad0e5ea2a
ToppCelldroplet-Marrow-nan-24m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BTRC RNF11

2.84e-041677254576e9863403d0d5e3046e61db1ad695d88fee4
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Hematopoietic|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RNF11 CARD19

3.23e-04178724ff23a0bb20c4373db14bfaad18b5fa5c7c78e76
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Hematopoietic-Megakaryocytic-Megakaryocyte-Mega|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RNF11 CARD19

3.23e-04178725caeffb70cbb868586bd260b44ccd3751bbfa615
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Hematopoietic-Megakaryocytic|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RNF11 CARD19

3.23e-0417872afc3220e2319cb38d59307db1b793a3915e1d5c4
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Hematopoietic-Megakaryocytic-Megakaryocyte|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RNF11 CARD19

3.23e-04178722c581a338bf33dbd2be9abe87d0a84f97dfb546f
ToppCellremission-Platelet|World / disease stage, cell group and cell class

RNF11 CARD19

3.60e-0418872fa69f20ef6b8ce620ba342f0984d40ddf259bc3f
ToppCellMegakaryocytic-erythropoietic-Megakaryo-cells-Platelet|Megakaryo-cells / Lineage, cell class and subclass

RNF11 CARD19

3.75e-0419272a061db719d87209b56d074afbdeab37aa0079419
ToppCellTCGA-Endometrium-Primary_Tumor-Endometrial_Adenocarcinoma-Endometrioid-1|TCGA-Endometrium / Sample_Type by Project: Shred V9

ADAMTS19 SPRY2

3.79e-0419372c2673d86f7d7b849788036032a93a6d136a70040
ToppCell10x5'-blood-Hematopoietic_Erythro-Mega|blood / Manually curated celltypes from each tissue

RNF11 CARD19

3.83e-0419472d0e7d35b5086834929c4bd39d4c6719b2d5fc71e
ToppCell10x5'-blood-Hematopoietic_Erythro-Mega-Megakaryocyte_early|blood / Manually curated celltypes from each tissue

RNF11 CARD19

3.83e-041947263dea7d630962761a70aa88e720ee35c22cbc81a
ToppCellCOVID-19_Mild-Classical_Monocyte-cMono_3|Classical_Monocyte / Disease condition and Cell class

SPRY2 CARD19

3.91e-041967215397ec27167bb2fb6fec120b68bf38fc71b2670
ToppCellCOVID-19_Mild-Classical_Monocyte-cMono_3|COVID-19_Mild / Disease condition and Cell class

SPRY2 CARD19

3.91e-0419672f245e929a286cb097130572e1027b4f01be8b04d
ToppCellCOVID-19-COVID-19_Mild-Myeloid-immature_Neutrophil|COVID-19_Mild / Disease, condition lineage and cell class

CDC25A SPRY2

4.03e-0419972e222b90caf45904d8f763574e7b6aac13333df92
ToppCell(1)_T_cell-(18)_cycling_gd_T|(1)_T_cell / shred on Cell_type and subtype

CDC25A SPRY2

4.03e-04199729369d0e4efe809e3e8757294ebebba5a47b30528
Drugestradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A

CDC25A BTRC SPRY2

2.02e-05192735955_UP
DrugVincamine [1617-90-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A

CDC25A BTRC SPRY2

2.18e-05197732327_UP
DrugNaftopidil dihydrochloride [57149-08-3]; Up 200; 8.6uM; MCF7; HT_HG-U133A

CDC25A BTRC SPRY2

2.21e-05198737331_UP
DrugH-7 dihydrochloride; Down 200; 100uM; PC3; HT_HG-U133A

CDC25A SPRY2

1.30e-03182725941_DN
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.36e-03186723518_DN
DrugGBR 12909 dihydrochloride [67469-78-7]; Up 200; 7.6uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.37e-03187723240_UP
DrugICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.37e-03187726872_DN
DrugRauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.42e-03190726274_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.42e-03190725223_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.42e-03190725218_DN
DrugTerfenadine [50679-08-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.43e-03191722227_DN
DrugICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.43e-03191721663_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.44e-03192725222_DN
DrugHyoscyamine (L) [101-31-5]; Down 200; 13.8uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.44e-03192722271_DN
DrugClomipramine hydrochloride [17321-77-6]; Down 200; 11.4uM; PC3; HT_HG-U133A

CDC25A BTRC

1.44e-03192724487_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.44e-03192723382_DN
DrugTiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.44e-03192726013_DN
DrugSecurinine [5610-40-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.44e-03192723470_UP
DrugColchicine [64-86-8]; Down 200; 10uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.46e-03193723213_DN
Drug(-)-depudecin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

CDC25A BTRC

1.46e-0319372982_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.46e-03193725215_DN
Drug5152487; Up 200; 10uM; MCF7; HT_HG-U133A_EA

BTRC SPRY2

1.46e-0319372896_UP
DrugMeclozine dihydrochloride [1104-22-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.46e-03193723285_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.46e-03193725602_DN
DrugTranexamic acid [1197-18-8]; Down 200; 25.4uM; PC3; HT_HG-U133A

CDC25A BTRC

1.47e-03194725762_DN
DrugTerfenadine [50679-08-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.47e-03194726823_DN
DrugSertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.47e-03194726811_DN
DrugIdoxuridine [54-42-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.47e-03194721480_DN
DrugAdamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.47e-03194723280_DN
DrugKawain [500-64-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.47e-03194722299_UP
Drug(-)-Isoproterenol hydrochloride [5984-95-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.47e-03194726833_DN
DrugDihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; PC3; HT_HG-U133A

CDC25A BTRC

1.49e-03195724502_DN
Drug17-AAG; Down 200; 1uM; SKMEL5; HG-U133A

CDC25A SPRY2

1.49e-0319572505_DN
DrugGallamine triethiodide [65-29-2]; Up 200; 4.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.49e-03195726215_UP
DrugPrednisone [53-03-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.49e-03195721478_DN
DrugPalmatine chloride [3486-67-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.49e-03195724957_DN
DrugClofazimine [2030-63-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.49e-03195725277_DN
DrugDiflunisal [22494-42-4]; Up 200; 16uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.49e-03195724794_UP
DrugCefoperazone dihydrate; Down 200; 5.8uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.49e-03195725424_DN
Drugclozapine; Down 200; 10uM; PC3; HT_HG-U133A

CDC25A BTRC

1.50e-03196724453_DN
DrugN-Acetyl-L-leucine [1188-21-2]; Down 200; 23uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.50e-03196726462_DN
DrugBerberine chloride [633-65-8]; Down 200; 10.8uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.50e-03196722770_DN
DrugApomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.50e-03196721505_UP
DrugDiphemanil methylsulfate [62-97-5]; Down 200; 10.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.50e-03196721494_DN
Drug6-mercaptopurine monohydrate; Down 200; 100uM; MCF7; HG-U133A

CDC25A BTRC

1.50e-0319672334_DN
DrugLovastatin [75330-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.50e-03196724978_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.50e-03196725240_DN
DrugDyclonine hydrochloride [536-43-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.50e-03196727022_DN
Drugikarugamycin; Up 200; 2uM; MCF7; HT_HG-U133A_EA

BTRC SPRY2

1.50e-0319672918_UP
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A

CDC25A BTRC

1.52e-03197724477_DN
DrugNicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.52e-03197725397_DN
DrugBergenin monohydrate [477-90-7]; Up 200; 11.6uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.52e-03197723467_UP
Drugclozapine; Down 200; 10uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197725226_DN
DrugSulindac [38194-50-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197721693_DN
DrugAtractyloside potassium salt [102130-43-8]; Down 200; 5uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197724717_DN
DrugFluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197725356_DN
DrugMinoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197721496_DN
DrugVerapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197725387_DN
DrugSulfabenzamide [127-71-9]; Down 200; 14.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197722814_DN
DrugThiamphenicol [15318-45-3]; Up 200; 11.2uM; PC3; HT_HG-U133A

BTRC SPRY2

1.52e-03197727274_UP
DrugFludrocortisone acetate [514-36-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197722328_UP
DrugFuraltadone hydrochloride [3759-92-0]; Up 200; 11uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197723413_UP
DrugGliclazide [21187-98-4]; Down 200; 12.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197722870_DN
DrugLincomycin hydrochloride [859-18-7]; Up 200; 9uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.52e-03197727411_UP
DrugGriseofulvin [126-07-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.54e-03198722293_UP
DrugMebendazole [31431-39-7]; Down 200; 13.6uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198724694_DN
DrugHydrocortisone base [50-23-7]; Up 200; 11uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198725284_UP
DrugTriprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198727008_UP
DrugParomomycin sulfate [1263-89-4]; Down 200; 5.6uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198723356_DN
DrugAltretamine [654-05-6]; Up 200; 19uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.54e-03198726467_UP
DrugSulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; PC3; HT_HG-U133A

CDC25A BTRC

1.54e-03198723711_DN
DrugTrimethobenzamide hydrochloride [554-92-7]; Up 200; 9.4uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.54e-03198721502_UP
DrugMK-886; Up 200; 1uM; MCF7; HG-U133A

CDC25A BTRC

1.54e-0319872264_UP
DrugN-phenylanthranilic acid; Up 200; 10uM; MCF7; HG-U133A

CDC25A SPRY2

1.54e-0319872317_UP
DrugAztreonam [78110-38-0]; Down 200; 9.2uM; PC3; HT_HG-U133A

CDC25A BTRC

1.54e-03198725110_DN
Drugrosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198726992_UP
DrugCiprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.54e-03198721522_UP
Drug2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A

CDC25A SPRY2

1.54e-03198725219_DN
DrugTheophylline monohydrate [5967-84-0]; Down 200; 20.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198723326_DN
Drugflufenamic acid; Up 200; 10uM; MCF7; HG-U133A

BTRC SPRY2

1.54e-0319872316_UP
DrugMoroxidine hydrochloride [3160-91-6]; Up 200; 19.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198725304_UP
DrugSulfabenzamide [127-71-9]; Down 200; 14.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198724979_DN
DrugBrompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198724131_DN
DrugZoxazolamine [61-80-3]; Up 200; 23.8uM; PC3; HT_HG-U133A

CDC25A BTRC

1.54e-03198726290_UP
DrugFenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.54e-03198726001_DN
Drugraloxifene hydrochloride; Down 200; 0.1uM; HL60; HG-U133A

CDC25A BTRC

1.54e-0319872388_DN
DrugDibucaine [85-79-0]; Down 200; 11.6uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.55e-03199721469_DN
DrugSulfamerazine [127-79-7]; Down 200; 15.2uM; MCF7; HT_HG-U133A

CDC25A BTRC

1.55e-03199726036_DN
Drug2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.55e-03199726974_UP
DrugNorethindrone [68-22-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

BTRC SPRY2

1.55e-03199727414_UP
DiseaseCleft palate, cleft lip

BTRC SPRY2

1.81e-0327972EFO_0003959, HP_0000175

Protein segments in the cluster

PeptideGeneStartEntry
MCSMPRSLWLGCSSL

BTRC

16

Q9Y297
MMTEWTPCSRTCGKG

ADAMTS19

981

Q8TE59
AWMSSMTTQVCCSPG

CARD19

126

Q96LW7
CMASLWTAPLVMRTT

CDC25A

236

P30304
LLSPRACMAMVGTSW

OR10P1

136

Q8NGE3
IDDWLMRSFTCPSCM

RNF11

126

Q9Y3C5
TRWSAMGVMSLFLPC

SPRY2

251

O43597